WallStreetZenWallStreetZen

NASDAQ: COLL
Collegium Pharmaceutical Revenue

OverviewForecastEarningsRevenue
DividendOwnership
Collegium Pharmaceutical revenue was $757.07M for the trailing 12 months ending Sep 30, 2025, with -31.7% growth year over year. Quarterly revenue for the quarter (Q3 2025) ending on Sep 30, 2025 was $209.4M, up 11.4% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, COLL annual revenue was $631.4M, with 11.4% growth year-over-year.

COLL past revenue growth

How has COLL's revenue growth performed historically?

Company
26.34%
Industry
2.54%
Market
20.42%
COLL's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
COLL's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
COLL's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

COLL revenue history

Current Revenue
$757.1M
Current Earnings
$58.4M
Current Profit Margin
7.7%

Be the first to know when COLL announces revenue.

COLL Revenue History By Year

COLL Yearly RevenueCOLL RevenueCOLL ChangeCOLL Revenue Growth
2024-12-31$631.45M$64.68M+11.41%
2023-12-31$566.77M$102.83M+22.17%
2022-12-31$463.93M$187.07M+67.56%
2021-12-31$276.87M-$33.15M-10.69%
2020-12-31$310.02M$13.32M+4.49%
2019-12-31$296.70M$16.29M+5.81%
2018-12-31$280.41M$251.94M+884.73%
2017-12-31$28.48M$26.77M+1,564.29%
2016-12-31$1.71MN/AN/A
2015-12-31$0.00N/AN/A
2014-12-31$0.00N/AN/A
2013-12-31$0.00N/AN/A

1 of 1

Collegium Pharmaceutical Revenue FAQ

What was COLL's revenue last quarter?

On Invalid Date, Collegium Pharmaceutical (NASDAQ: COLL) reported Q3 2025 revenue of $209.36 million up 31.42% year over year. In the same quarter last year, Collegium Pharmaceutical's revenue was $159.30 million.

What was Collegium Pharmaceutical's revenue in 2024?

Collegium Pharmaceutical's annual revenue for the twelve months ending Dec 31, 2024 was $631.45 million, a 11.41% increase year over year.

How much does Collegium Pharmaceutical make in a day?

Based on Collegium Pharmaceutical annual revenue for the past five years, COLL makes an average of $1,232,346.85 per day.

What was Collegium Pharmaceutical's annual revenue growth in the past year?

As of Q4 2025, Collegium Pharmaceutical's revenue has grown 26.34% year over year. This is 23.8 percentage points higher than the US Drug Manufacturers - Specialty & Generic industry revenue growth rate of 2.54%. Collegium Pharmaceutical's revenue in the past year totaled $757.07 million.

How much does Collegium Pharmaceutical make in a year?

Collegium Pharmaceutical's revenue by year for the past five years is:
  • Collegium Pharmaceutical's revenue for the twelve months ending Dec 31, 2024 was $631.45 million, a 11.41% increase year over year.
  • Collegium Pharmaceutical's annual revenue for Dec 31, 2023 was $566.77 million, a 22.17% increase from 2022.
  • Collegium Pharmaceutical's annual revenue for 2022 was $463.93 million, a 67.56% increase from 2021.
  • Collegium Pharmaceutical's annual revenue for 2021 was $276.87 million, a 10.69% decrease from 2020.
  • Collegium Pharmaceutical's annual revenue for 2020 was $310.02 million, a 4.49% increase from 2019.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.